Bill Text: IL HR0837 | 2023-2024 | 103rd General Assembly | Introduced

---

Bill Title: Declares the month of June 2024 as Migraine and Headache Awareness Month in the State of Illinois.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced) 2024-05-25 - Referred to Rules Committee [HR0837 Detail]

Download: Illinois-2023-HR0837-Introduced.html

---

HR0837 LRB103 40960 ECR 74019 r
HOUSE RESOLUTION
WHEREAS, There are more than 300 medically recognized
headache diseases, including cluster headaches and migraine;
and
WHEREAS, Migraine is a genetic, neurobiological disease
characterized by episodes known as attacks; and
WHEREAS, Headache diseases impact one in four households
in the United States, with more than 42 million Americans
living with headache diseases, including approximately four
million who have chronic migraine, meaning they experience 15
or more migraine attacks each month; and
WHEREAS, Headache diseases are three to four times more
prevalent in women, and Native/Indigenous communities have the
highest prevalence of disabling headaches in the United
States; and
WHEREAS, Significant disparities in diagnosis, treatment,
and outcomes for headache diseases persist, particularly
affecting Black, Hispanic, and Native/Indigenous populations
who face underdiagnosis and inadequate treatment; and
WHEREAS, It is estimated that 40 to 50% of persons living

HR0837 - 2 - LRB103 40960 ECR 74019 r
with migraine disease are undiagnosed; and
WHEREAS, Migraine is the second leading cause of global
disability, and notably one of the most disabling for women
under 50 years old; and
WHEREAS, Approximately one in 1,000 people in the United
States live with cluster headache disease, medically referred
to as one of the most painful conditions a human can
experience; and
WHEREAS, Veterans returning from Iraq and Afghanistan have
two to four times the incidence of migraine compared to the
general population, likely due to Traumatic Brain Injuries
(TBI), and posttraumatic headache occurs in up to 92% of
military personnel who have sustained mild TBIs; and
WHEREAS, Headache diseases are an economic issue, costing
U.S. companies upwards of $78 billion dollars each year in
direct and indirect costs; and
WHEREAS, The effects of headache diseases are experienced
on a spectrum, presenting with significantly different levels
of intensity, frequency, and disability; and
WHEREAS, Migraine disease impacts all systems of the body,

HR0837 - 3 - LRB103 40960 ECR 74019 r
and symptoms may include intense pain, nausea and vomiting,
sensitivity to light, sound, smell, and touch, visual
disturbances, tinnitus, chills, fatigue, anomic aphasia, or
trouble finding words, impaired cognitive function, and
numbness and weakness, lasting for four to 72 hours on
average; and
WHEREAS, Stigma and misinformation related to headache
disease have stifled research and advances in treatment; and
WHEREAS, All persons living with headache diseases deserve
fair, equal, timely, and affordable access to new and
innovative treatments to live their lives to their fullest
potential; therefore, be it